Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)-Reference-Cited by-同舟云学术

Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)

Published:2020-11-06 Issue:3 Volume:62 Page:571-580
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Chen Mei-ting¹^ORCID,Fu Xiao-hong¹²³,Huang He¹,Wang Zhao¹,Fang Xiao-jie¹,Yao Yu-Yi¹,Ren Quan-Guang¹,Chen Ze-geng¹,Lin Tong-yu¹

Affiliation:

1. Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

2. Department of Medical Oncology, Shenzhen Nanshan People's Hospital, Shenzhen, China

3. Department of Medical Oncology, Affiliated Shenzhen Sixth Hospital of Guangdong Medical University, Shenzhen, China

Funder

Science and Technology Planning Project of Guangdong Province

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1839658

Reference44 articles.

1. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology